Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?

被引:29
作者
Nijst, Petra [1 ,2 ]
Martens, Pieter [1 ,2 ]
Mullens, Wilfried [1 ,3 ]
机构
[1] Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium
[2] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium
[3] Hasselt Univ, Biomed Res Inst, Fac Med & Life Sci, Diepenbeek, Belgium
关键词
Heart failure with recovered ejection fraction; Myocardial recovery; Reverse remodeling; CARDIAC-RESYNCHRONIZATION THERAPY; VENTRICULAR EJECTION FRACTION; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; CONVERTING-ENZYME-INHIBITOR; BRAIN NATRIURETIC PEPTIDE; LONG-TERM; SYSTOLIC DYSFUNCTION; ASSIST DEVICE; DOUBLE-BLIND; EXERCISE CAPACITY;
D O I
10.1016/j.pcad.2017.05.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In an important number of heart failure (HF) patients substantial or complete myocardial recovery occurs. In the strictest sense, myocardial recovery is a return to both normal structure and function of the heart. HF patients with myocardial recovery or recovered ejection fraction (EF; HFrecEF) are a distinct population of HF patients with different underlying etiologies, demographics, comorbidities, response to therapies and outcomes compared to HF patients with persistent reduced (HFrEF) or preserved ejection fraction (HFpEF). Improvement of left ventricular EF has been systematically linked to improved quality of life, lower rehospitalization rates and mortality. However, mortality and morbidity in HFrecEF patients remain higher than in the normal population. Also, persistent abnormalities in biomarker and gene expression profiles in these patients lends weight to the hypothesis that pathological processes are ongoing. Currently, there remains a lack of data to guide the management of HFrecEF patients. This review will discuss specific characteristics, pathophysiology, clinical implications and future needs for HFrecEF. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:226 / 236
页数:11
相关论文
共 123 条
  • [61] Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure
    Konstam, MA
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (06) : 867 - 871
  • [62] EFFECTS OF THE ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR ENALAPRIL ON THE LONG-TERM PROGRESSION OF LEFT-VENTRICULAR DYSFUNCTION IN PATIENTS WITH HEART-FAILURE
    KONSTAM, MA
    ROUSSEAU, MF
    KRONENBERG, MW
    UDELSON, JE
    MELIN, J
    STEWART, D
    DOLAN, N
    EDENS, TR
    AHN, S
    KINAN, D
    HOWE, DM
    KILCOYNE, L
    METHERALL, J
    BENEDICT, C
    YUSUF, S
    POULEUR, H
    [J]. CIRCULATION, 1992, 86 (02) : 431 - 438
  • [63] Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction A Meta-Analytic Approach
    Kramer, Daniel G.
    Trikalinos, Thomas A.
    Kent, David M.
    Antonopoulos, George V.
    Konstam, Marvin A.
    Udelson, James E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (05) : 392 - 406
  • [64] KRUM H, 1995, CIRCULATION, V92, P212
  • [65] DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE LONG-TERM EFFICACY OF CARVEDILOL IN PATIENTS WITH SEVERE CHRONIC HEART-FAILURE
    KRUM, H
    SACKNERBERNSTEIN, JD
    GOLDSMITH, RL
    KUKIN, ML
    SCHWARTZ, B
    PENN, J
    MEDINA, N
    YUSHAK, M
    HORN, E
    KATZ, SD
    LEVIN, HR
    NEUBERG, GW
    DELONG, G
    PACKER, M
    [J]. CIRCULATION, 1995, 92 (06) : 1499 - 1506
  • [66] Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure
    Krum, H
    Gu, AG
    WilshireClement, M
    SacknerBernstein, J
    Goldsmith, R
    Medina, N
    Yushak, M
    Miller, M
    Packer, M
    [J]. AMERICAN HEART JOURNAL, 1996, 131 (02) : 337 - 341
  • [67] Novel Predictors of Left Ventricular Reverse Remodeling in Individuals With Recent-Onset Dilated Cardiomyopathy
    Kubanek, Milos
    Sramko, Marek
    Maluskova, Jana
    Kautznerova, Dana
    Weichet, Jiri
    Lupinek, Petr
    Vrbska, Jana
    Malek, Ivan
    Kautzner, Josef
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (01) : 54 - 63
  • [68] Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance
    Kubo, H
    Margulies, KB
    Piacentino, V
    Gaughan, JP
    Houser, SR
    [J]. CIRCULATION, 2001, 104 (09) : 1012 - 1018
  • [69] Epidemiology of “Heart Failure with Recovered Ejection Fraction”: What do we do After Recovery?
    Kuttab J.S.
    Kiernan M.S.
    Vest A.R.
    [J]. Current Heart Failure Reports, 2015, 12 (6) : 360 - 366
  • [70] The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%)
    Lam, Carolyn S. P.
    Solomon, Scott D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (10) : 1049 - 1055